Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
NSPR
Deeply overvalued
InspireMD, Inc.
Price$0.48
Model IV$0.21
P/IV4.38
Premium +129%
Return to IV: -56.3%
Market implies +4.7%/yr
vs model +18.9% · below model
NTRB
Valuation N/A
NutriBand Inc.
Price$6.05
Model IV—
P/IV—
Market implies +40.3%/yr
vs model +14.6% · above model
NTRBW
Valuation N/A
NutriBand Inc.
Price$0.55
Model IV—
P/IV—
Market implies +9.4%/yr
NUWE
Valuation N/A
Nuwellis, Inc.
Price$0.68
Model IV—
P/IV—
Market implies -39.8%/yr
vs model +2.0% · below model
NVCR
Valuation N/A
NovoCure Ltd
Price$14.22
Model IV—
P/IV—
Market implies +33.6%/yr
vs model +5.2% · above model
NVNO
Valuation N/A
enVVeno Medical Corp
Price$8.18
Model IV—
P/IV—
Limited data — see page
NVST
Fairly valued
Envista Holdings Corp
Price$22.72
Model IV$23.59
P/IV1.01
Discount 4%
Return to IV: +3.8%
Market implies +5.9%/yr
vs model +7.6% · in line
NXGL
Valuation N/A
NEXGEL, INC.
Price$0.15
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +50.0% · below model
NXGLW
Valuation N/A
NEXGEL, INC.
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr
NXL
Valuation N/A
Nexalin Technology, Inc.
Price$4.11
Model IV—
P/IV—
Market implies +108.5%/yr
vs model +20.3% · above model
NYXH
Valuation N/A
Nyxoah SA
Price$1.35
Model IV—
P/IV—
Limited data — see page
OBIO
Valuation N/A
Orchestra BioMed Holdings, Inc.
Price$5.73
Model IV—
P/IV—
Market implies +43.1%/yr
vs model +15.0% · above model
OFIX
Deeply undervalued
Orthofix Medical Inc.
Price$9.00
Model IV$44.28
P/IV0.21
Discount 80%
Return to IV: +392.0%
Market implies -30.0%/yr
vs model +15.4% · below model
OM
Valuation N/A
Outset Medical, Inc.
Price$4.09
Model IV—
P/IV—
Limited data — see page
OSRH
Valuation N/A
OSR Holdings, Inc.
Price$0.21
Model IV—
P/IV—
Market implies +11.7%/yr
vs model +15.0% · below model
OSRHW
Deeply undervalued
OSR Health, Inc.
Price$0.01
Model IV$0.09
P/IV0.22
Discount 89%
Return to IV: +800.0%
Market implies -37.5%/yr
vs model +15.0% · below model
OSUR
Valuation N/A
ORASURE TECHNOLOGIES INC
Price$3.80
Model IV—
P/IV—
Market implies +19.9%/yr
vs model +2.0% · above model
PAVM
Valuation N/A
PAVmed Inc.
Price$2.69
Model IV—
P/IV—
Market implies +82.6%/yr
vs model +2.0% · above model
PDEX
Deeply overvalued
PRO DEX INC
Price$62.21
Model IV$44.41
P/IV1.46
Premium +40%
Return to IV: -28.6%
Market implies -0.7%/yr
vs model +15.0% · below model
PEN
Deeply overvalued
Penumbra Inc
Price$317.52
Model IV$221.14
P/IV1.44
Premium +44%
Return to IV: -30.4%
Market implies -4.4%/yr
vs model +17.1% · below model
PFSA
Valuation N/A
Profusa, Inc.
Price$1.49
Model IV—
P/IV—
Market implies +16.8%/yr
PHG
Valuation N/A
KONINKLIJKE PHILIPS NV
Price$24.30
Model IV—
P/IV—
Limited data — see page
PLRZ
Valuation N/A
Polyrizon Ltd.
Price$8.87
Model IV—
P/IV—
Limited data — see page
PLSE
Valuation N/A
PULSE BIOSCIENCES, INC.
Price$49.98
Model IV—
P/IV—
Market implies +150.0%/yr
PLSM
Valuation N/A
Pulsenmore Ltd.
Price$1.92
Model IV—
P/IV—
Limited data — see page
PMI
Valuation N/A
Picard Medical, Inc.
Price$9.68
Model IV—
P/IV—
Market implies +31.2%/yr
vs model +12.5% · above model
POCI
Deeply undervalued
PRECISION OPTICS CORPORATION, INC.
Price$4.67
Model IV$9.70
P/IV0.56
Discount 52%
Return to IV: +107.9%
Market implies -20.3%/yr
vs model +15.6% · below model
PODD
Deeply undervalued
INSULET CORP
Price$134.47
Model IV$249.75
P/IV0.58
Discount 46%
Return to IV: +85.7%
Market implies +7.6%/yr
vs model +20.7% · below model
PRCT
Deeply undervalued
PROCEPT BioRobotics Corp
Price$17.90
Model IV$40.36
P/IV0.65
Discount 56%
Return to IV: +125.5%
Market implies -14.4%/yr
vs model +50.0% · below model
PROF
Valuation N/A
Profound Medical Corp.
Price$6.91
Model IV—
P/IV—
Market implies +25.7%/yr
PSTV
Valuation N/A
PLUS THERAPEUTICS, INC.
Price$3.84
Model IV—
P/IV—
Market implies +70.9%/yr
vs model +15.0% · above model
PYPD
Valuation N/A
PolyPid Ltd.
Price$4.90
Model IV—
P/IV—
Limited data — see page
QTEX
Valuation N/A
QTREX Quantum Ltd.
Price$1.69
Model IV—
P/IV—
Market implies +89.1%/yr
vs model +15.0% · above model
QTI
Deeply undervalued
QT IMAGING HOLDINGS, INC.
Price$2.60
Model IV$3.80
P/IV1.32
Discount 32%
Return to IV: +46.1%
Market implies -12.6%/yr
vs model +15.0% · below model
RCEL
Deeply overvalued
AVITA Medical, Inc.
Price$13.33
Model IV$3.73
P/IV2.94
Premium +257%
Return to IV: -72.0%
Market implies +19.1%/yr
vs model +25.1% · below model
RGNT
Valuation N/A
REGENTIS BIOMATERIALS LTD.
Price$1.70
Model IV—
P/IV—
Limited data — see page
RMD
Deeply undervalued
RESMED INC
Price$226.73
Model IV$375.92
P/IV0.51
Discount 40%
Return to IV: +65.8%
Market implies +3.6%/yr
vs model +11.9% · below model
RVP
Deeply undervalued
RETRACTABLE TECHNOLOGIES INC
Price$0.66
Model IV$1.26
P/IV0.54
Discount 47%
Return to IV: +90.3%
Market implies -19.1%/yr
vs model +2.0% · below model
SGHT
Valuation N/A
Sight Sciences, Inc.
Price$8.47
Model IV—
P/IV—
Market implies +28.3%/yr
SGP
Valuation N/A
SpyGlass Pharma, Inc.
Price$24.62
Model IV—
P/IV—
Limited data — see page
SI
Deeply undervalued
SHOULDER INNOVATIONS, INC.
Price$17.89
Model IV$35.42
P/IV0.49
Discount 49%
Return to IV: +98.0%
Market implies -11.7%/yr
vs model +49.6% · below model
SIBN
Deeply overvalued
SI-BONE, Inc.
Price$18.86
Model IV$10.92
P/IV1.29
Premium +73%
Return to IV: -42.1%
Market implies +4.3%/yr
vs model +22.2% · below model
SINT
Valuation N/A
Sintx Technologies, Inc.
Price$2.11
Model IV—
P/IV—
Market implies +23.2%/yr
SKIN
Deeply undervalued
SkinHealth Systems Inc.
Price$0.57
Model IV$1.76
P/IV0.38
Discount 68%
Return to IV: +209.3%
Market implies -16.4%/yr
vs model +4.0% · below model
SMTI
Deeply undervalued
Sanara MedTech Inc.
Price$35.05
Model IV$68.98
P/IV0.33
Discount 49%
Return to IV: +96.8%
Market implies -13.4%/yr
vs model +43.8% · below model
SNN
Deeply undervalued
SMITH & NEPHEW PLC
Price$26.96
Model IV$47.06
P/IV0.57
Discount 43%
Return to IV: +74.6%
Market implies -0.3%/yr
vs model +8.3% · below model
SNOA
Deeply undervalued
Sonoma Pharmaceuticals, Inc.
Price$1.16
Model IV$6.57
P/IV0.19
Discount 82%
Return to IV: +466.4%
Market implies -37.5%/yr
vs model +11.5% · below model
SNWV
Deeply undervalued
SANUWAVE Health, Inc.
Price$5.85
Model IV$23.83
P/IV0.69
Discount 75%
Return to IV: +307.8%
Market implies -26.9%/yr
vs model +40.3% · below model
SOLV
Deeply undervalued
Solventum Corp
Price$86.41
Model IV$130.34
P/IV0.68
Discount 34%
Return to IV: +50.8%
Market implies +0.7%/yr
vs model +7.2% · below model
SPAI
Valuation N/A
Safe Pro Group Inc.
Price$4.27
Model IV—
P/IV—
Market implies +78.5%/yr
vs model +2.0% · above model
SRTS
Deeply overvalued
Sensus Healthcare, Inc.
Price$2.97
Model IV$1.17
P/IV2.59
Premium +154%
Return to IV: -60.6%
Market implies +12.1%/yr
vs model +2.0% · above model
SSII
Deeply overvalued
SS Innovations International, Inc.
Price$2.63
Model IV$0.85
P/IV4.66
Premium +211%
Return to IV: -67.8%
Market implies +4.1%/yr
vs model +15.0% · below model
STE
Undervalued
STERIS plc
Price$210.76
Model IV$254.59
P/IV0.82
Discount 17%
Return to IV: +20.8%
Market implies +5.5%/yr
vs model +9.7% · below model
STEX
Valuation N/A
Streamex Corp.
Price$0.51
Model IV—
P/IV—
Market implies +91.6%/yr
STIM
Deeply undervalued
Neuronetics, Inc.
Price$2.14
Model IV$3.07
P/IV0.94
Discount 30%
Return to IV: +43.4%
Market implies -5.3%/yr
vs model +28.2% · below model
STSS
Valuation N/A
STSS
Price$1.95
Model IV—
P/IV—
Limited data — see page
STVN
Deeply overvalued
Stevanato Group S.p.A.
Price$19.21
Model IV$9.88
P/IV2.20
Premium +94%
Return to IV: -48.6%
Market implies +6.7%/yr
vs model +7.6% · in line
STXS
Valuation N/A
Stereotaxis, Inc.
Price$1.11
Model IV—
P/IV—
Market implies +43.8%/yr
vs model +2.0% · above model
SYK
Fairly valued
STRYKER CORP
Price$276.97
Model IV$294.72
P/IV0.93
Discount 6%
Return to IV: +6.4%
Market implies +7.4%/yr
vs model +10.0% · in line
TCMD
Deeply undervalued
TACTILE SYSTEMS TECHNOLOGY INC
Price$22.12
Model IV$38.96
P/IV0.63
Discount 43%
Return to IV: +76.1%
Market implies +1.2%/yr
vs model +11.5% · below model